Key result
RNAi-based therapeutics targeting conserved viral genes demonstrated potent preclinical antiviral effects against Japanese encephalitis virus, including >90% suppression of viral RNA.
Why the study?
Limited efficacy against emerging genotypes and incomplete coverage of vaccines and vector control necessitate alternative antiviral approaches for Japanese encephalitis virus.
Design
Review
Authors
Loading...
RNAi suppression of Japanese encephalitis virus is hypothesis-generating; leaves open clinical translation due to delivery and safety barriers.
RNAi therapeutics show significant preclinical promise for treating Japanese encephalitis virus, though clinical translation remains hindered by delivery and safety challenges.
Kumar et al. (2025) conducted a review in Japanese encephalitis virus (JEV). RNA interference (RNAi) therapeutics was evaluated. RNAi-based therapeutics targeting conserved viral genes demonstrated potent preclinical antiviral effects against Japanese encephalitis virus, including >90% suppression of viral RNA.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: